Research & Literature

Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.

Al-Hamadani M, Habermann TM, Cerhan JR, et al.

American journal of hematology 2015; (90(9)):790-5 doi:10.1002/ajh.24086.

Treatment of low-grade gastric MALT lymphoma using Helicobacter pylori eradication.

Grgov S, Katić V, Krstić M, et al.

Vojnosanitetski pregled 2015; (72(5)):431-6 doi:10.2298/vsp1505431g.

Evaluating the efficacy of a self-guided Web-based CBT intervention for reducing cancer-distress: a randomised controlled trial.

Beatty L, Koczwara B, Wade T

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016; (24(3)):1043-51 doi:10.1007/s00520-015-2867-6.

Histologic transformation in marginal zone lymphomas†.

Conconi A, Franceschetti S, Aprile von Hohenstaufen K, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2015; (26(11)):2329-35 doi:10.1093/annonc/mdv368.

Lymphoma Remission by Interferon-Free HCV Eradication Without Chemotherapy.

Lim LY, La D, Cserti-Gazdewich CM, Shah H

ACG case reports journal 2015; (3(1)):69-70 doi:10.14309/crj.2015.104.

Perceived diagnostic delay and cancer-related distress: a cross-sectional study of patients with colorectal cancer.

Miles A, McClements PL, Steele RJ, et al.

Psycho-oncology 2017; (26(1)):29-36 doi:10.1002/pon.4093.

Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.

Gong EJ, Ahn JY, Jung HY, et al.

Gut and liver 2016; (10(5)):706-13 doi:10.5009/gnl15510.

NF-κB deregulation in splenic marginal zone lymphoma.

Spina V, Rossi D

Seminars in cancer biology 2016; (39()):61-7.

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Kiesewetter B, Willenbacher E, Willenbacher W, et al.

Blood 2017; (129(3)):383-385 doi:10.1182/blood-2016-06-720599.

Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment.

Tadmor T, Polliack A

Best practice & research. Clinical haematology 2017; (30(1-2)):92-98 doi:10.1016/j.beha.2016.08.026.

Primary hepatic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type: A case report and literature review.

Dong S, Chen L, Chen Y, Chen X

Medicine 2017; (96(13)):e6305 doi:10.1097/MD.0000000000006305.

Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma.

Campos-Martín Y, Martínez N, Martínez-López A, et al.

Haematologica 2017; (102(8)):e310-e312 doi:10.3324/haematol.2016.161711.

A MALT lymphoma prognostic index.

Thieblemont C, Cascione L, Conconi A, et al.

Blood 2017; (130(12)):1409-1417 doi:10.1182/blood-2017-03-771915.

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Salar A, Domingo-Domenech E, Panizo C, et al.

Blood 2017; (130(15)):1772-1774 doi:10.1182/blood-2017-07-795302.

Anxiety and Depression in Cancer Survivors.

Yi JC, Syrjala KL

The Medical clinics of North America 2017; (101(6)):1099-1113 doi:10.1016/j.mcna.2017.06.005.

Results of Upfront Therapy for Marginal Zone Lymphoma.

Ortega JL, Cabanillas F, Rivera N, et al.

Clinical lymphoma, myeloma & leukemia 2017; (17(12)):879-883 doi:10.1016/j.clml.2017.09.014.

Effective management strategies for patients with marginal zone lymphoma.

Rosand CB, Valla K, Flowers CR, Koff JL

Future oncology (London, England) 2018; (14(12)):1213-1222 doi:10.2217/fon-2017-0480.

Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?

Kalpadakis C, Pangalis GA, Angelopoulou MK, et al.

Best practice & research. Clinical haematology 2018; (31(1)):65-72 doi:10.1016/j.beha.2017.10.011.

NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.

Vo DN, Alexia C, Allende-Vega N, et al.

Oncoimmunology 2018; (7(4)):e1409322 doi:10.1080/2162402X.2017.1409322.

Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.

Farhat L, Dara J, Duberstein S, De A

Drug safety - case reports 2018; (5(1)):22 doi:10.1007/s40800-018-0087-y.

Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.

Kalpadakis C, Pangalis GA, Sachanas S, et al.

Blood 2018; (132(6)):666-670 doi:10.1182/blood-2018-02-833608.

Validation of the Marginal Zone Lymphoma International Prognostic Index.

Hong J, Cho J, Ko YH, et al.

Annals of hematology 2019; (98(2)):457-464 doi:10.1007/s00277-018-3516-1.

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

Iannitto E, Bellei M, Amorim S, et al.

British journal of haematology 2018; (183(5)):755-765 doi:10.1111/bjh.15641.

Pleural Mucosa-associated Lymphoid Tissue Lymphoma with Trisomy 18.

Okamoto N, Hayashi E, Tsukino M

Internal medicine (Tokyo, Japan) 2019; (58(6)):891-892 doi:10.2169/internalmedicine.1780-18.

Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin.

Kheterpal MK, Dai J, Geller S, et al.

Journal of the American Academy of Dermatology 2019; (81(4)):970-976 doi:10.1016/j.jaad.2019.01.037.

FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma.

Vaxman I, Bernstine H, Kleinstern G, et al.

Hematological oncology 2019; (37(2)):168-175 doi:10.1002/hon.2578.

Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.

Cheah CY, Opat S, Trotman J, Marlton P

Internal medicine journal 2019; (49(9)):1070-1080 doi:10.1111/imj.14268.

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Leonard JP, Trneny M, Izutsu K, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(14)):1188-1199 doi:10.1200/JCO.19.00010.

Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results.

Toyoda K, Maeshima AM, Nomoto J, et al.

Annals of hematology 2019; (98(7)):1675-1687 doi:10.1007/s00277-019-03671-5.

Rare Primary Pulmonary Marginal Zone Lymphoma Presenting with Incidental Pulmonary Nodules.

Ullah S, Ali M, Song M

Case reports in pulmonology 2019; (2019()):7031868 doi:10.1155/2019/7031868.

Splenic marginal zone lymphoma associated with hepatitis B virus infection, remission after viral treatment, and splenectomy: A case report and review of the literature.

Ababou M, Mahtat EM, Jennane S, et al.

Hematology/oncology and stem cell therapy 2021; (14(2)):153-155 doi:10.1016/j.hemonc.2019.05.007.

POD24 in MZL: a means to an end or an end point in itself?

Maurer MJ

Blood 2019; (134(10)):787-788 doi:10.1182/blood.2019002305.

Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable.

Campbell KL, Winters-Stone KM, Wiskemann J, et al.

Medicine and science in sports and exercise 2019; (51(11)):2375-2390 doi:10.1249/MSS.0000000000002116.

Splenic marginal zone lymphoma treated with laparoscopic splenectomy: A case report.

Koyama R, Minagawa N, Maeda Y, et al.

International journal of surgery case reports 2019; (65()):288-291 doi:10.1016/j.ijscr.2019.11.008.

Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome.

Gorodetskiy VR, Probatova NA, Vasilyev VI

International journal of rheumatic diseases 2020; (23(4)):540-548 doi:10.1111/1756-185X.13800.

Extra-Nodal Marginal Zone Lymphoma (MZL) of MALT CD20+ of the Ocular Adnexa: Case Report.

Rajabto W, Kevinsyah AP

Maedica 2020; (15(1)):126-128 doi:10.26574/maedica.2020.15.1.126.

Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis.

Xie YL, He CY, Wei SQ, et al.

Chinese medical journal 2020; (133(11)):1337-1346 doi:10.1097/CM9.0000000000000813.

Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.

Furqan F, Watson G, Samaniego F, et al.

Leukemia & lymphoma 2020; (61(12)):2980-2984 doi:10.1080/10428194.2020.1791849.

Morphological and immunohistochemical approaches to the diagnosis of Hashimoto thyroiditis and mucosa associated lymphoid tissue lymphomas: An audit.

Rency K, Santha S, Dain CP

Rare tumors 2020; (12()):2036361320972560 doi:10.1177/2036361320972560.

Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.

Munoz J, Follows GA, Nastoupil LJ

Targeted oncology 2021; (16(3)):295-308 doi:10.1007/s11523-021-00802-9.

Epidemiology of Marginal Zone Lymphoma.

Cerhan JR, Habermann TM

Annals of lymphoma 2021; (5()) doi:10.21037/aol-20-28.

Helicobacter pylori and Gastric Cancer.

Kim J, Wang TC

Gastrointestinal endoscopy clinics of North America 2021; (31(3)):451-465 doi:10.1016/j.giec.2021.03.003.

Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors.

Benedict C, Fisher S, Schapira L, et al.

Psycho-oncology 2022; (31(1)):9-20 doi:10.1002/pon.5763.

Risk-tailored treatment of splenic marginal zone lymphoma.

Castelli R, Balzarotti M, Salvi E, et al.

Anti-cancer drugs 2022; (33(1)):e36-e42 doi:10.1097/CAD.0000000000001165.

CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.

Hsu A, Kurt H, Zayac AS, Olszewski AJ

Leukemia & lymphoma 2022; (63(1)):31-42 doi:10.1080/10428194.2021.1973670.

Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.

Vela V, Juskevicius D, Dirnhofer S, et al.

Virchows Archiv : an international journal of pathology 2022; (480(2)):403-413 doi:10.1007/s00428-021-03186-3.

Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.

Bastidas-Mora G, Beà S, Navarro A, et al.

British journal of haematology 2022; (196(1)):146-155 doi:10.1111/bjh.17815.

Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma.

Quéro L, Labidi M, Bollet M, et al.

World journal of gastrointestinal oncology 2021; (13(10)):1453-1465 doi:10.4251/wjgo.v13.i10.1453.

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

Jacobson CA, Chavez JC, Sehgal AR, et al.

The Lancet. Oncology 2022; (23(1)):91-103 doi:10.1016/S1470-2045(21)00591-X.

Recent Advances in the Genetic of MALT Lymphomas.

Rodríguez-Sevilla JJ, Salar A

Cancers 2021; (14(1)) doi:10.3390/cancers14010176.

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.

Alderuccio JP, Arcaini L, Watkins MP, et al.

Blood advances 2022; (6(7)):2035-2044 doi:10.1182/bloodadvances.2021006844.

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.

Phillips T, Chan H, Tam CS, et al.

Blood advances 2022; (6(11)):3472-3479 doi:10.1182/bloodadvances.2021006083.

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.

Scarfò L, Ferrari S, Frustaci AM, et al.

Blood advances 2022; (6(18)):5356-5359 doi:10.1182/bloodadvances.2022007138.

Cutaneous mucosa-associated lymphoid tissue lymphoma complicating Sjögren's syndrome: A case report and review of literature.

Liu Y, Zhu J, Huang YH, et al.

World journal of clinical cases 2022; (10(14)):4509-4518 doi:10.12998/wjcc.v10.i14.4509.

The potential of pirtobrutinib in multiple B-cell malignancies.

Jensen JL, Mato AR, Pena C, et al.

Therapeutic advances in hematology 2022; (13()):20406207221101697 doi:10.1177/20406207221101697.

Mind-body practices for cancer-related symptoms management: an overview of systematic reviews including one hundred twenty-nine meta-analyses.

Casuso-Holgado MJ, Heredia-Rizo AM, Gonzalez-Garcia P, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(12)):10335-10357 doi:10.1007/s00520-022-07426-3.

The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies.

Liu K, Li J, Xu G

Virulence 2022; (13(1)):2012-2021 doi:10.1080/21505594.2022.2146380.

Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.

Podestà MA, Mescia F, Ricchiuto A, et al.

Rheumatology (Oxford, England) 2023; (62(8)):2850-2854 doi:10.1093/rheumatology/keac716.

Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.

Nakamura S, Hojo M

Journal of clinical medicine 2022; (12(1)) doi:10.3390/jcm12010120.

[Clinical Impact Assessment and Utilization Prospects of the t(11:18) Chromosomal Translocation in Gastric MALT Lymphoma in Koreans: A Single Center Retrospective Analysis].

Jung H, Shin DW, Cheung DY, et al.

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2023; (81(1)):29-35 doi:10.4166/kjg.2022.129.

Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

Athni TS, Barmettler S

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.

Tam CS, Trotman J, Opat S, et al.

Blood advances 2023; (7(12)):2884-2887 doi:10.1182/bloodadvances.2022008990.

Management of Marginal Zone Lymphoma: A Canadian Perspective.

Peters A, Keating MM, Nikonova A, et al.

Current oncology (Toronto, Ont.) 2023; (30(2)):1745-1759 doi:10.3390/curroncol30020135.

Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia.

Faehling S, Coelho M, Floerchinger A, et al.

HemaSphere 2023; (7(3)):e840 doi:10.1097/HS9.0000000000000840.

Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2.

Fattizzo B, Rampi N, Barcellini W

Blood reviews 2023; (60()):101077 doi:10.1016/j.blre.2023.101077.

Transformations of marginal zone lymphomas and lymphoplasmacytic lymphomas: Report from the 2021 SH/EAHP Workshop.

Cook JR, Amador C, Czader M, et al.

American journal of clinical pathology 2023; doi:10.1093/ajcp/aqad034.

Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review.

Rivero A, Mozas P, Magnano L, López-Guillermo A

Frontiers in oncology 2023; (13()):1170394 doi:10.3389/fonc.2023.1170394.

Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal.

Raderer M, Kiesewetter B, Du MQ

Therapeutic advances in medical oncology 2023; (15()):17588359231183565 doi:10.1177/17588359231183565.

Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis.

Zhang Y, Ma Z, Wang Y, et al.

Expert review of clinical pharmacology 2023; (16(9)):855-863 doi:10.1080/17512433.2023.2238602.

Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly.

Junlén HR, Sonnevi K, Lindén O, et al.

EJHaem 2023; (4(3)):647-655 doi:10.1002/jha2.696.

Marginal zone lymphoma: 2023 update on diagnosis and management.

Cheah CY, Seymour JF

American journal of hematology 2023; (98(10)):1645-1657 doi:10.1002/ajh.27058.

The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.

Zamò A, van den Brand M, Climent F, et al.

Virchows Archiv : an international journal of pathology 2023; (483(3)):317-331 doi:10.1007/s00428-023-03633-3.

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.

Opat S, Tedeschi A, Hu B, et al.

Blood advances 2023; (7(22)):6801-6811 doi:10.1182/bloodadvances.2023010668.

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).

Neelapu SS, Chavez JC, Sehgal AR, et al.

Blood 2024; (143(6)):496-506 doi:10.1182/blood.2023021243.

Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Gordon MJ, Feng L, Strati P, et al.

Cancer 2024; (130(6)):876-885 doi:10.1002/cncr.35114.

Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.

Epperla N, Zhao Q, Moyo T, et al.

Blood advances 2024; (8(3)):549-552 doi:10.1182/bloodadvances.2023011698.

[Chinese expert consensus on the diagnosis and management of ocular adnexal extranodal marginal zone mucosa-associated lymphoid tissue lymphoma (2023 edition)].

, , , et al.

Zhonghua zhong liu za zhi [Chinese journal of oncology] 2024; (46(4)):296-303 doi:10.3760/cma.j.cn112152-20230727-00042.

MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.

Zhang LF, Zhang Y, Shui RH, et al.

Diagnostic pathology 2024; (19(1)):60 doi:10.1186/s13000-024-01481-6.

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.

Arcaini L, Bommier C, Alderuccio JP, et al.

EClinicalMedicine 2024; (72()):102592 doi:10.1016/j.eclinm.2024.102592.

Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis.

Brazel D, Grant C, Cabal A, et al.

Frontiers in immunology 2024; (15()):1334899 doi:10.3389/fimmu.2024.1334899.

PI3K Inhibitors in Hematology: When One Door Closes….

Skånland SS, Okkenhaug K, Davids MS

Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(17)):3667-3675 doi:10.1158/1078-0432.CCR-24-0967.

Long-term Clinical Efficacy of Radiotherapy for Patients with Stage I-II Gastric Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A Retrospective Multi-institutional Study.

Jeong JU, Lee HC, Song JH, et al.

Cancer research and treatment 2025; (57(2)):570-579 doi:10.4143/crt.2024.651.

Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.

Wang H, Zhang Y, Li Z, Bai O

Frontiers in immunology 2024; (15()):1466859 doi:10.3389/fimmu.2024.1466859.

Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.

Grover NS, Annunzio K, Watkins M, et al.

Blood cancer journal 2024; (14(1)):182 doi:10.1038/s41408-024-01162-z.

Reduced-dose Radiation Therapy for Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Multi-Institutional Prospective Study (KROG 16-18).

Jeon SH, Chang JH, Kim IH, et al.

International journal of radiation oncology, biology, physics 2025; (121(4)):1000-1005 doi:10.1016/j.ijrobp.2024.10.020.

A pilot randomized controlled trial of a yoga program for alleviating cancer-related fatigue and psychological distress in women with gynecological cancer.

Ma X, Shang M, Wong CL, et al.

European journal of oncology nursing : the official journal of European Oncology Nursing Society 2025; (74()):102731 doi:10.1016/j.ejon.2024.102731.

[Characteristics of Gastric Mucosa-associated Lymphoid Tissue Lymphoma in Korea].

Kim TW, Kim JS

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2024; (84(6)):243-250 doi:10.4166/kjg.2024.108.

Genetic alterations and their prognostic impact in marginal zone lymphoma: a meta-analysis.

Li X, Lin Y, An L

Annals of hematology 2025; (104(3)):1307-1315 doi:10.1007/s00277-024-06175-z.

Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.

Zhang Q, Yan W, Li H, Peng H

Current treatment options in oncology 2025; (26(2)):142-155 doi:10.1007/s11864-025-01293-w.

Marginal B-cell lymphoma: A 10-year retrospective study at national institute of hematology and blood transfusion, Vietnam.

Vu BD, Nguyen HQ, Le CQ, et al.

SAGE open medicine 2025; (13()):20503121251334508 doi:10.1177/20503121251334508.

Concurrent chronic follicular conjunctivitis and conjunctival MALT lymphoma potentially caused by Chlamydia pneumoniae.

Chen YL, Jung SM, Hsiao CH

IDCases 2025; (40()):e02251 doi:10.1016/j.idcr.2025.e02251.

Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma.

Bakker M, Kuipers MT, Kersten MJ, et al.

Current opinion in oncology 2025; (37(5)):393-400 doi:10.1097/CCO.0000000000001160.

Evidence- and Consensus-Based Recommendations for the Screening, Diagnosis, and Management of Secondary Hypogammaglobulinemia in Patients With Systemic Autoimmune Rheumatic Diseases by the Taiwan College of Rheumatology Experts.

Tsao YP, Chen HH, Hsieh TY, et al.

International journal of rheumatic diseases 2025; (28(6)):e70310 doi:10.1111/1756-185X.70310.

Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study.

Ito A, Ito K, Iriyama C, et al.

Cureus 2025; (17(10)):e95858 doi:10.7759/cureus.95858.

Infection screening prior to Ocrelizumb initiation in patients with Multiple Sclerosis (MS): Concise clinical recommendation based on a modified Delphi consensus on behalf of the Iranian MS -infectious disease group.

Paybast S, Abutorabi-Zarchi M, Ashtari F, et al.

Multiple sclerosis and related disorders 2026; (105()):106824 doi:10.1016/j.msard.2025.106824.

Higher incomplete remission rate of ocular extranodal marginal zone B-cell lymphoma in hepatitis B virus infectious patients.

Chen YP, Yang IH, Tsai YJ, et al.

Orbit (Amsterdam, Netherlands) 2026; (45(1)):79-86 doi:10.1080/01676830.2025.2553657.

Prognostic outcome of extranodal marginal zone B-cell lymphoma: a nationwide cohort.

Nam SY, Jo J

Scientific reports 2025; doi:10.1038/s41598-025-32259-5.

Mucosal-Associated Lymphoid Tissue Lymphoma in Southeast Asia: A 15-Year Retrospective Multicenter Study.

Prayongratana K, Thamgrang T, Laoruangroj C, et al.

Hematology reports 2025; (17(6)) doi:10.3390/hematolrep17060063.

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Patel K, Vose JM, Nasta SD, et al.

Blood advances 2026; (10(7)):2441-2451 doi:10.1182/bloodadvances.2025017489.

Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.

Palomba ML, Schuster SJ, Karmali R, et al.

Lancet (London, England) 2026; (407(10532)):963-975 doi:10.1016/S0140-6736(25)02435-3.

Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma: a retrospective study in regions with a high prevalence of Helicobacter pylori infection.

Kim JW, Yeom DH, Park SY, et al.

BMC gastroenterology 2026; (26(1)).

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management.

Noor WD, Seymour JF, Cheah CY

American journal of hematology 2026; (101(6)):1320-1340 doi:10.1002/ajh.70289.

Utility of MEF2B immunohistochemistry in distinguishing follicular lymphoma and marginal zone lymphoma in diagnostically challenging cases.

Dalland JC, Oyedeji OS, Viswanatha DS, et al.

Journal of hematopathology 2026; (19(1)).